share_log

Zimmer Biomet Holdings' (NYSE:ZBH) Performance Is Even Better Than Its Earnings Suggest

Zimmer Biomet Holdings' (NYSE:ZBH) Performance Is Even Better Than Its Earnings Suggest

齊默巴奧米特控股(紐交所:ZBH)的表現甚至比其盈利所示更好
Simply Wall St ·  11/07 18:30

Even though Zimmer Biomet Holdings, Inc.'s (NYSE:ZBH) recent earnings release was robust, the market didn't seem to notice. Our analysis suggests that investors might be missing some promising details.

儘管齊默巴奧米特控股(NYSE:ZBH)最近的盈利發佈強勁,市場似乎並未注意到。我們的分析表明,投資者可能錯過了一些有前途的細節。

big
NYSE:ZBH Earnings and Revenue History November 7th 2024
紐交所:ZBH 盈利和營業收入歷史 2024年11月7日

The Impact Of Unusual Items On Profit

除了稀釋之外,還應該注意的是,萬集科技在過去12個月中因不尋常項目獲得了價值人民幣3.5萬元的利潤。雖然我們希望看到利潤增加,但當這些不尋常項目對利潤做出重大貢獻時,我們會更加謹慎。我們對全球大部分上市公司的數據進行了分析,發現不尋常項目往往是一次性的。這正如我們所期望的那樣,因爲這些提升被描述爲"不尋常"。相對於其利潤而言,萬集科技在2021年12月前的不尋常項目貢獻大。因此,我們可以推斷出,這些不尋常項目正在使其財務利潤顯著增強。

Importantly, our data indicates that Zimmer Biomet Holdings' profit was reduced by US$309m, due to unusual items, over the last year. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And that's hardly a surprise given these line items are considered unusual. Assuming those unusual expenses don't come up again, we'd therefore expect Zimmer Biomet Holdings to produce a higher profit next year, all else being equal.

重要的是,我們的數據顯示,齊默巴奧米特控股的利潤由於飛凡事項在過去一年中減少了30900萬美元。看到飛凡事項導致公司利潤減少從來不是一件好事,但值得慶幸的是,事情可能很快就會好轉。我們研究了成千上萬家上市公司,發現飛凡事項往往是一次性的。鑑於這些項目被視爲飛凡,這並不奇怪。假設這些飛凡費用不會再次出現,我們因此預計齊默巴奧米特控股在明年會產生更高的利潤,其他情況不變。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓您想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看基於其估計的未來盈利能力的互動圖表。

Our Take On Zimmer Biomet Holdings' Profit Performance

我們對齊默巴奧米特控股公司的利潤表現持有以下觀點:

Unusual items (expenses) detracted from Zimmer Biomet Holdings' earnings over the last year, but we might see an improvement next year. Based on this observation, we consider it likely that Zimmer Biomet Holdings' statutory profit actually understates its earnings potential! Furthermore, it has done a great job growing EPS over the last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. If you want to do dive deeper into Zimmer Biomet Holdings, you'd also look into what risks it is currently facing. Every company has risks, and we've spotted 2 warning signs for Zimmer Biomet Holdings you should know about.

過去一年,齊默巴奧米特控股的異常項目(支出)減少了收入,但我們可能會在明年看到改善。根據這一觀察結果,我們認爲齊默巴奧米特控股的法定利潤實際上低估了其收益潛力!此外,過去一年它在增長每股收益方面做得很好。本文的目標是評估我們能否依靠法定收益來反映公司的潛力,但還有很多要考慮的因素。如果您想更深入了解齊默巴奧米特控股,您還應該了解它目前面臨的風險。每家公司都有風險,我們已經發現了齊默巴奧米特控股的2個警示標誌,您應該知道。

Today we've zoomed in on a single data point to better understand the nature of Zimmer Biomet Holdings' profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

今天,我們將重點放在一個單一數據點上,以更好地了解齊默巴奧米特控股利潤的性質。但有許多其他方法可以幫助您了解一家公司。例如,許多人認爲高股本回報率表明良好的業務經濟狀況,而另一些人則喜歡「追蹤資金」並尋找內部人士正在購買的股票。因此,您可能希望查看這份免費的公司收藏,其中包含高股本回報率的公司,或者這份擁有高內部所有權的股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論